Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Teleflex (TFX), Cigna (CI) and BioNTech SE (BNTX)

Tipranks - Tipranks - Tue Apr 14, 6:02AM CDT

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Teleflex (TFX), Cigna (CI) and BioNTech SE (BNTX).

Claim 30% Off TipRanks

Teleflex (TFX)

Teleflex received a Hold rating and a $135.00 price target from Bank of America Securities analyst Travis Steed today. The company’s shares closed last Friday at $118.39.

According to TipRanks.com, Steed is a 3-star analyst with an average return of 2.4% and a 48.9% success rate. Steed covers the Healthcare sector, focusing on stocks such as Kestra Medical Technologies Ltd., Bausch + Lomb Corporation, and Zimmer Biomet Holdings. ;'>

Teleflex has an analyst consensus of Moderate Buy, with a price target consensus of $134.43.

See today’s best-performing stocks on TipRanks >>

Cigna (CI)

Bank of America Securities analyst Joanna Gajuk maintained a Buy rating on Cigna today and set a price target of $378.00. The company’s shares closed last Friday at $271.25, close to its 52-week low of $262.03.

According to TipRanks.com, Gajuk is a 2-star analyst with an average return of 0.7% and a 52.2% success rate. Gajuk covers the Healthcare sector, focusing on stocks such as Concentra Group Holdings Parent, Inc., BrightSpring Health Services, Inc., and Brookdale Senior Living. ;'>

Cigna has an analyst consensus of Strong Buy, with a price target consensus of $344.08, representing a 23.8% upside. In a report issued on March 30, Bernstein also maintained a Buy rating on the stock with a $358.00 price target.

BioNTech SE (BNTX)

In a report released today, Tazeen Ahmad from Bank of America Securities reiterated a Buy rating on BioNTech SE, with a price target of $130.00. The company’s shares closed last Friday at $95.50.

According to TipRanks.com, Ahmad is a 2-star analyst with an average return of 0.0% and a 50.7% success rate. Ahmad covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, KalVista Pharmaceuticals, and Bicara Therapeutics Inc. ;'>

BioNTech SE has an analyst consensus of Strong Buy, with a price target consensus of $136.81, representing a 47.5% upside. In a report issued on April 10, Morgan Stanley also maintained a Buy rating on the stock with a $126.00 price target.

Read More on TFX:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).